SG11201901402PA - Pharmaceutical Composition for Delivery of Peptide - Google Patents
Pharmaceutical Composition for Delivery of PeptideInfo
- Publication number
- SG11201901402PA SG11201901402PA SG11201901402PA SG11201901402PA SG11201901402PA SG 11201901402P A SG11201901402P A SG 11201901402PA SG 11201901402P A SG11201901402P A SG 11201901402PA SG 11201901402P A SG11201901402P A SG 11201901402PA SG 11201901402P A SG11201901402P A SG 11201901402PA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- combination
- peptide
- pct
- metal
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 229910052751 metal Inorganic materials 0.000 abstract 3
- 239000002184 metal Substances 0.000 abstract 3
- 239000003638 chemical reducing agent Substances 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 abstract 1
- 229910002091 carbon monoxide Inorganic materials 0.000 abstract 1
- 229910052804 chromium Inorganic materials 0.000 abstract 1
- 239000011651 chromium Substances 0.000 abstract 1
- 230000037406 food intake Effects 0.000 abstract 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 230000017854 proteolysis Effects 0.000 abstract 1
- 229910052720 vanadium Inorganic materials 0.000 abstract 1
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/32—Manganese; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 28 March 2019 (28.03.2019) WIPO I PCT 11111111111111011111111111111110111110100111111111111111111111111110011111011110111111 (10) International Publication Number WO 2019/058273 Al (51) International Patent Classification: A61K 31/00 (2006.01) (21) International Application Number: PCT/[132018/057209 (22) International Filing Date: 19 September 2018 (19.09.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 201711033555 21 September 2017 (21.09.2017) IN (71) Applicant: ANYA BIOPHARM INC. [CN/CN]; 6F., No. 378, Changchun Rd., Taipei, 10487 (TW). (72) Inventors; and (71) Applicants: GSCHLIESSER, Siegfried [AT/CN]; 8F., No.16-6, Fuzhou St., Zhongzheng Dist., Taipei City, 100 (TW). DESAI, Bhushan Dhruvkumar [IN/IN]; Lodha Aqua, Antartica C-304 Mira Road East, Thane, Maharash- tra 401107 (IN). (74) Agent: KHURANA & KHURANA, ADVOCATES & IP ATTORNEYS; E-13, UPSIDC, Site-IV, Behind-Grand Venice, Kasna Road, Greater Noida, National Capital Re- gion, Uttar Pradesh 201310 (IN). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE -0!C N oc O O C (54) Title: PHARMACEUTICAL COMPOSITIONS FOR DELIVERY OF PEPTIDE (57) : The present invention relates to a pharmaceutical composition including: a pharmaceutically effective amount of at least one peptide; and a pharmaceutically acceptable amount of a combination of: (a) at least one metal in form of any or a combination of a salt thereof and a complex thereof; and (b) at least one reducing agent, wherein, the at least one metal is selected from any or a combination of: vanadium, chromium and manganese, and wherein the combination of (a) at least one metal in form of any or a combination of a salt and a complex and (b) at least one reducing agent affords protection, at least in part, to the at least one peptide from proteolytic degradation upon ingestion thereof.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201711033555 | 2017-09-21 | ||
| PCT/IB2018/057209 WO2019058273A1 (en) | 2017-09-21 | 2018-09-19 | Pharmaceutical compositions for delivery of peptide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201901402PA true SG11201901402PA (en) | 2019-04-29 |
Family
ID=65810723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901402PA SG11201901402PA (en) | 2017-09-21 | 2018-09-19 | Pharmaceutical Composition for Delivery of Peptide |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US11389474B2 (en) |
| EP (1) | EP3509573B1 (en) |
| JP (3) | JP2021506731A (en) |
| KR (1) | KR102542671B1 (en) |
| CN (1) | CN109843274A (en) |
| AU (1) | AU2018336135B2 (en) |
| BR (1) | BR112020005363A2 (en) |
| CA (1) | CA3072864A1 (en) |
| CL (1) | CL2020000440A1 (en) |
| DK (1) | DK3509573T3 (en) |
| EA (1) | EA202090317A1 (en) |
| ES (1) | ES2951918T3 (en) |
| HR (1) | HRP20230799T1 (en) |
| HU (1) | HUE062587T2 (en) |
| IL (1) | IL273451B2 (en) |
| MX (1) | MX2020002437A (en) |
| PL (1) | PL3509573T3 (en) |
| PT (1) | PT3509573T (en) |
| SG (1) | SG11201901402PA (en) |
| SI (1) | SI3509573T1 (en) |
| TW (1) | TWI751379B (en) |
| WO (1) | WO2019058273A1 (en) |
| ZA (1) | ZA202001393B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI751379B (en) * | 2017-09-21 | 2022-01-01 | 奧孟亞股份有限公司 | Pharmaceutical composition for delivery of peptide |
| PL3886814T3 (en) | 2018-11-26 | 2025-04-07 | The Procter & Gamble Company | Solid pharmaceutical preparation containing lipoic acid and use thereof |
| JP7610410B2 (en) * | 2019-03-08 | 2025-01-08 | アニヤ バイオファーム インク． | Oral parathyroid hormone analogue formulations and treatment |
| KR102216578B1 (en) * | 2019-09-05 | 2021-02-17 | 주식회사 아이큐어비앤피 | Oral pharmaceutical composition comprising teriparatide and method for preparing the same |
| KR102253318B1 (en) * | 2020-06-02 | 2021-05-18 | (주)위바이오트리 | A metal compound having the phase transformation and preparing a method of the same |
| EP4226918A1 (en) * | 2022-02-15 | 2023-08-16 | Filip Majewski | Pharmaceutical single dosage form for oral delivery of peptides |
| WO2025037993A1 (en) | 2023-08-13 | 2025-02-20 | Filip Majewski | Dosage form for peptide agents |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6376549B1 (en) * | 1998-09-17 | 2002-04-23 | Akesis Pharmaceuticals, Inc. | Metforimin-containing compositions for the treatment of diabetes |
| CA2587391A1 (en) * | 2004-11-16 | 2006-05-26 | Nu-Tein Co., Inc. | Compositions useful to treat ocular neovascular diseases and macular degeneration |
| US9259456B2 (en) | 2005-09-06 | 2016-02-16 | Oramed Pharmaceuticals Inc. | Methods and compositions for oral administration of proteins |
| ES2366034T3 (en) * | 2005-12-23 | 2011-10-14 | N.V. Nutricia | COMPOSITION THAT INCLUDES POLYINSATURATED FATTY ACIDS, PROTEINS, MANGANESE AND / OR MOLIBDENE AND NUCLEOSIDES / NUCLEOTIDES FOR THE TREATMENT OF DEMENTIA. |
| AU2011349715A1 (en) * | 2010-12-21 | 2013-07-04 | Nestec S.A. | Methods and compositions suitable for managing blood glucose in animals |
| WO2012140155A1 (en) | 2011-04-14 | 2012-10-18 | Novo Nordisk A/S | Fatty acid acylated amino acids for oral peptide delivery |
| CN103861086A (en) | 2014-03-07 | 2014-06-18 | 东营倍康生物科技有限公司 | Preparation method of bitter gourd peptide arabinose composite tablet |
| EP3006045B3 (en) | 2014-10-07 | 2021-03-17 | Cyprumed GmbH | Pharmaceutical formulations for the oral delivery of peptide or protein drugs |
| CA2997343A1 (en) * | 2015-10-07 | 2017-04-13 | Cyprumed Gmbh | Pharmaceutical formulations for the oral delivery of peptide drugs |
| TWI751379B (en) * | 2017-09-21 | 2022-01-01 | 奧孟亞股份有限公司 | Pharmaceutical composition for delivery of peptide |
-
2018
- 2018-09-13 TW TW107132324A patent/TWI751379B/en active
- 2018-09-19 SI SI201830954T patent/SI3509573T1/en unknown
- 2018-09-19 CN CN201880003234.8A patent/CN109843274A/en active Pending
- 2018-09-19 PL PL18849471.0T patent/PL3509573T3/en unknown
- 2018-09-19 HR HRP20230799TT patent/HRP20230799T1/en unknown
- 2018-09-19 US US16/324,008 patent/US11389474B2/en active Active
- 2018-09-19 CA CA3072864A patent/CA3072864A1/en active Pending
- 2018-09-19 ES ES18849471T patent/ES2951918T3/en active Active
- 2018-09-19 BR BR112020005363-5A patent/BR112020005363A2/en unknown
- 2018-09-19 HU HUE18849471A patent/HUE062587T2/en unknown
- 2018-09-19 JP JP2019528818A patent/JP2021506731A/en active Pending
- 2018-09-19 WO PCT/IB2018/057209 patent/WO2019058273A1/en unknown
- 2018-09-19 SG SG11201901402PA patent/SG11201901402PA/en unknown
- 2018-09-19 AU AU2018336135A patent/AU2018336135B2/en active Active
- 2018-09-19 KR KR1020197003703A patent/KR102542671B1/en active Active
- 2018-09-19 EP EP18849471.0A patent/EP3509573B1/en active Active
- 2018-09-19 DK DK18849471.0T patent/DK3509573T3/en active
- 2018-09-19 PT PT188494710T patent/PT3509573T/en unknown
- 2018-09-19 EA EA202090317A patent/EA202090317A1/en unknown
- 2018-09-19 MX MX2020002437A patent/MX2020002437A/en unknown
-
2020
- 2020-02-21 CL CL2020000440A patent/CL2020000440A1/en unknown
- 2020-03-04 ZA ZA2020/01393A patent/ZA202001393B/en unknown
- 2020-03-19 IL IL273451A patent/IL273451B2/en unknown
-
2022
- 2022-06-02 US US17/831,017 patent/US12208118B2/en active Active
- 2022-07-12 JP JP2022111628A patent/JP2022132375A/en active Pending
-
2024
- 2024-06-13 JP JP2024096206A patent/JP2024111060A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201901402PA (en) | Pharmaceutical Composition for Delivery of Peptide | |
| SG11201907034PA (en) | Methods of treating influenza | |
| SG11201803686UA (en) | Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease | |
| SG11201903938XA (en) | Acylated glp-1/glp-2 dual agonists | |
| SG11201908547VA (en) | Hydrogel cross-linked hyaluronic acid prodrug compositions and methods | |
| SG11201907604UA (en) | Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan | |
| SG11201810423XA (en) | Pd-1 / pd-l1 inhibitors for cancer treatment | |
| SG11201908465QA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201808138YA (en) | Substituted indole derivatives as dengue viral replication inhibitors | |
| SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
| SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
| SG11201811442UA (en) | Formulation of a peptide vaccine | |
| SG11201811209QA (en) | Oral gastroretentive formulations and uses thereof | |
| SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
| SG11201907804QA (en) | Pharmaceutical composition comprising selexipag | |
| SG11201408054RA (en) | Pegylated oxm variants | |
| SG11201909837YA (en) | Methods for treating lung disorders | |
| SG11201810396QA (en) | Pegylated carfilzomib compounds | |
| SG11201906959RA (en) | Aryl hydrocarbon receptor (ahr) modulator compounds | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201407536UA (en) | Topical pharmaceutical compositions comprising terbinafine and urea | |
| SG11201903431SA (en) | Sstr-targeted conjugates and particles and formulations thereof | |
| SG11201809976PA (en) | Protection of plant extracts and compounds from degradation | |
| SG11201901070YA (en) | Formulations for oral administration of active agents | |
| SG11201900471VA (en) | Combination therapy for copd |